Kernspintomographie zum Metastasen-Screening? Ein prospektiver Vergleich mit der Skelettszintigraphie^[*]

Zusammenfassung

Bei 102 Patienten mit Tumoren mit häufiger Skelettmetastasierung, wurde im Vergleich zur Skelettszintigraphie (SkSz) der Stellenwert der Kernspintomographie (KST) von Wirbelsäule, Becken, Femora und proximalen Tibiae zum Metastasen-Screening geprüft. Alle Patienten hatten in der SkSz keinen Metastasen-Hinweis, 96 (94%) auch bei der KST. Nur bei 6% der Patienten fanden sich mit KST im Knochenmark Herdbefunde. Dies bedeutet, daß eine 94%ige Wahrscheinlichkeit auf Metastasenfreiheit gegeben ist, wenn die SkSz normal ausfällt, weshalb sie nach wie vor die Methode der Wahl zum Screening nach ossären Metastasen ist. Trotz hoher Sensitivität und Spezifität kann die KST mit der momentanen Routinetechnik die SkSz derzeit wegen längerer Untersuchungszeiten, höherer Kosten und fehlender Ganzkörperaufnahme noch nicht ersetzen, erscheint aber bei radiologisch negativen fraglichen Befunden der SkSz indiziert.

Summary

To define the value of magnetic resonance imaging (MRI) in screening for bone metastases (BM) compared to bone scintigraphy (BSc) 102 patients with tumours with frequent BM were examined also by MRI of spine, plevis, femora, and proximal tibiae. All patients had normal BSc and 96 (94%) normal MRI. Only 6% of the patients had focal abnormalities within the bone marrow. This indicates that there is a 94% probability of absence of BM if BSc is normal. Therefore, BSc should currently remain the method of choice for screening for BM. Despite MRI is sensitive and specific, with the common technique up to now it should not be used instead of BSc in screening because of costs, duration, and lack of whole body examination. MRI is a valuable adjunct in equivocal findings in BSc with negative results on radiographs.

Schlüsselwörter

Skelettmetastasen - Kernspintomographie - Magnetresonanztomographie - Skelettszintigraphie - Knochenmark - Screening

Key words

Bone metastases - magnetic resonance imaging - bone scintigraphy - bone marrow - screening

• Literatur

• 1 Abrains HL, Spiro R, Goldstein N. Metastases in Carcinoma: analysis of 1000 autopsied cases. Cancer 1950; 3: 336-40.
• 2 Algra PR, Bloem JL, Tissing H. et al. Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 1991; 11: 219-32.
• 3 Avrahami E, Radmor R, Dally O, Hadar H. Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scan. J Comput Assist Tomogr 1989; 13: 598-602.
• 4 Bauer R, van de Fliert E, Langhammer HR, All-gayer B, Stepan R. Szintigraphie und Kernspintomographie des Skeletts und Knochenmarks. Der Nuklearmediziner 1989; 5: 303-20.
• 5 Berger U, Bettelheim R, Mansi J. et al. The relationship between micrometastases of the bone marrow, histopathologic features of the primary tumour in breast cancer and prognosis. Am Clin Pathol 1988; 12: 333.
• 6 Berrettoni BA, Carter JR. Current concepts review. Mechanisms of cancer metastasis to bone. J Bone Joint Surg [Am] 1986; 68: 308-12.
• 7 Bohndorf K. Knochenmetastasen. In: MR Tomographie des Skeletts und der peripheren Weichteile. Bohndorf K. ed. Berlin, Heidelberg. New York: Springer; 1991: 71-4.
• 8 Daffner RH, Lupetin AR, Dash N. et al. MRI in the detection of malignant infiltration of bone marrow. Am J Radiol 1986; 146: 353-8.
• 9 Dearnaley DP, Ormerod MC, Sloane JP. et al. Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J Roy Soc Med 1983; 76: 359.
• 10 Duncker CM, Carrio I, Berna L. Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med 1990; 31: 1450-5.
• 11 Frank JA, Ling A, Patronas NJ. Detection of malignant bone tumors: MR imaging versus scintigraphy. Am J Radiol 1990; 155: 1043.
• 12 Haubold-Reuter BG, Duewell S, Schilcher B, Marcincek B, von Schulthess GK. The value of bone scintigraphy, bone marrow scintigraphy and fast spinecho magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med 1993; 20: 1063-9.
• 13 Hirsch FR, Hansen HH. Bone marrow involvement in small cell anaplastic carcinoma of the lung. Cancer 1988; 46: 206-11.
• 14 Hotze A, Ruhlmann J, Bockisch A, Briele B, Bier-sack J. Vergleich der Knochenmarkszintigraphie und Magnetresonanztomographie beim Plas-mocytom. Der Nuklearmediziner 1989; 5: 337-41.
• 15 Ihde DC, Simms B, Matthews MJ. et al. Bone marrow metastases of small cell carcinoma of the lung: frequency, description, and influence on che-motherapeutic toxicity and prognosis. Blood 1979; 53: 677-86.
• 16 Jelinek JS, Redmond III J, Perry JJ. et al. Small cell lung cancer: staging with MR imaging. Radiology 1990; 177: 837-42.
• 17 Jones Al, Williams MP, Powles TJ. et al. Magnetic resonance imaging in detection of skeletal metastases in patients with breast cancer. Br J Cancer 1990; 62: 296-8.
• 18 Kamby C, Guldhammer B, Vejborg I. et al. The presence of tumour cells in bone marrow at the time of first recurrence of breast cancer. Cancer 1987; 60: 1306.
• 19 Kattapuram SV, Khurana JS, Scott JA, El-Khoury GY. Negative scintigraphy with positive magnetic resonance imaging in bone metastases. Skeletal Radiol 1990; 19: 113-6.
• 20 Krishnamurthy GT, Tubis M, Hiss J, Blahd WH. Distribution pattern of metastatic bone disease: a need for total body skeletal imaging. J Am Med Ass 1977; 237: 2504-6.
• 21 Landys K. Prognostic value of bone marrow biopsy in breast cancer. Cancer 1982; 49: 513.
• 22 Layer G, Jarosch K. Magnetresonanztomographie des Knochenmarks zum Nachweis von Metastasen solider Tumoren. Radiologe 1992; 32: 502-8.
• 23 Devithan N, Byrne RE, Bromer RN. et al. The value of the bone scan and bone marrow biopsy in staging small cell lung cancer. Cancer 1985; 56: 652.
• 24 Linden A, Zankovich R, Theissen P, Diehl V, Schicha H. Malignant lymphoma: bone marrow imaging versus biopsy. Radiology 1989; 173: 335.
• 25 Mansi JL, Berger U, McDonnel T. et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989; 7: 445.
• 26 McKillop JH. Bone scanning in metastatic disease. In: Bone scanning in clinical practice. Fogelman I. ed. Berlin, Heidelberg, New York: Springer; 1987: 41-60.
• 27 McKillop JH. Bone scanning in primary bone tumours and marrow disorders. In: Bone scanning in clinical practice. Fogelman I. ed. Berlin, Heidelberg, New York: Springer; 1987: 61-72.
• 28 McNeil BJ. Value of bone scanning in neoplastic disease. Semin Nucl Med 1984; 14: 277-86.
• 29 Meinshausen J, Choritz H, Georgi A. Frequency of skeletal metastases as revealed by routinely taken bone marrow biopsies. Virchows Arch [A] 1980; 389: 409.
• 30 Otsuika N, Fugunaka M, Sone T. et al. The usefulness of bone marrow scintigraphy in the detection of bone metastases from prostatic cancer. Eur J Nucl Med 1985; 11: 319-22.
• 31 Pantel K, lzbicki JR, Angstwurm M. et al. lmmuno-cytological detection of bone marrow micrometastases in operable non small cell lung cancer. Cancer Res 1993; 33: 1027-31.
• 32 Porter BA, Shields AF, Olson DO. Magnetic resonance imaging of bone marrow disorders. Radiol Clin N Am 1986; 24: 269-89.
• 33 Redding HW, Coombes RC, Monaghan P. et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983; ii: 1271.
• 34 Reske SN, Karstens HJ, Glöckner W, Schwarz A, Steinstässer A, Ammon J, Buell U. Radioimmuno-imaging of bone marrow. Results in patients with breast cancer and skeletal metastases and patients with malignant lymphomas 1989; II: 299.
• 35 Reske SN. Recent advances in bone marrow scanning. Eur J Nucl Med 1991; 18: 203-21.
• 36 Ridell B, Landys K. Incidence and histopathology of metastases of mammary carcinoma in biopsies from the posterior iliac crest. Cancer 1979; 44: 1782.
• 37 Rieden K. Knochenmetastasen. Berlin, Heidelberg, New York: Springer; 1988
• 38 Scher HI, Yagoda A. Bone metastases: pathogenesis, treatment and rationale for the use of resorption inhibitors. Am J Med 1987; 82 (Suppl 2 A): 6.
• 39 Schlimok G, Funke L, Holzmann B. Micrometasta-tic cancer cells in bone marrow at the time of first recurrence: in vitro detection with anticytokeratin and in vivo labelling with anti-17-lA monoclonal antibodies. Proc Natl Acad Sei 1987; 84: 8672.
• 40 Smolarz K, Jungehülsing M, Krug B. et al. Kernspintomographie des Knochenmarks bei Karzi-nompa-tienten mit einer solitären Mehranreicherung im Skelettszintigramm. Nucl-Med 1990; 29: 269-73.
• 41 Soudah B, Stauch G, Sprindler B, Nicolai U, Geor-gii A. Histologischer Tumortyp und Knochenmarksmetastasen von Carcinomen der Brustdrüse. Verh Dtsch Ges Pathol 1985; 69: 338.